3075 - Everolimus: Finance (Answered)

Dan Jarvis
To ask the Secretary of State for Health, what plans he has to provide funding for everolimus.

George Freeman

It is for National Health Service commissioners to make funding decisions on individual treatments taking into account guidance from the National Institute for Health and Care Excellence (NICE) where available. Cancer drugs that are not routinely funded by the NHS may be available through the Cancer Drugs Fund.

Everolimus is available through the Cancer Drugs Fund for two indications: (i) in combination with exemestane, for advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy and (ii) for the second-line treatment of advanced renal cell carcinoma.

Everolimus is currently being appraised by NICE for the prevention of organ rejection in liver transplantation and for use in renal transplantation.

Everolimus is also licensed for use in the treatment of Tuberous Sclerosis and Subependymal Giant Cell Astrocytoma (SEGA). NICE has not been asked to develop guidance on the use of everolimus for these conditions. It is therefore for NHS commissioners to take funding decisions based on an assessment of the available evidence.

In January this year, NHS England launched a three-month public consultation to seek people’s views about proposals for a set of principles which NHS England should apply when making investment decisions and a new process for developing commissioning policies for specific treatments, drugs and medical devices. These elements are part of a Framework, which, when finalised, will underpin every decision NHS England makes about specialised services investments.

Now that the consultation has ended, NHS England has advised that work is underway to determine whether any amendments are required to its proposals as a result of the feedback received.